Valeant starts to deal with debts
It’s been more than a year since analysts first said Valeant…
The FDA is reviewing the requirements for opioids
Opioid makers may face a new task, which, in fact, is partly…
An Important Intermediate Success of Novartis
The entire pharmaceutical industry with great interest watched…
FDA approved Mylotarg
In 2010, Pfizer decided to withdraw from the US market Mylotarg,…
FDA: apps will be approved quite easily
According to estimate by The Economist, last year there were…
Efficiency savings for cancer drugs
Bringing a new oncology drug to market in the U.S. is expensive.…